Clinical and laboratory features and response to treatment in patients presenting with vitamin B12 deficiency-related neurological syndromes.

Simple item page
dc.contributor.authorAaron, Sen_US
dc.contributor.authorKumar, Sudhiren_US
dc.contributor.authorVijayan, Jen_US
dc.contributor.authorJacob, Jen_US
dc.contributor.authorAlexander, Men_US
dc.contributor.authorGnanamuthu, Cen_US
dc.date.accessioned2005-03-05en_US
dc.date.accessioned2009-06-03T10:18:39Z
dc.date.available2005-03-05en_US
dc.date.available2009-06-03T10:18:39Z
dc.date.issued2005-03-05en_US
dc.description.abstractAIMS AND OBJECTIVES: To study the clinical and laboratory features of patients admitted with vitamin B12 deficiency-related (B12def) neurological syndromes. SETTINGS AND DESIGN: A hospital-based retrospective and prospective study conducted at a referral teaching hospital. MATERIALS AND METHODS: Consecutive patients admitted with vitamin B12 deficiency-related neurological disorders during a three-year period from June 2000 to May 2003 were included. Data regarding clinical and laboratory features were obtained. Follow-up was done at least six months following treatment with parenteral vitamin B12. Chi-square test was used for statistical analysis. RESULTS: A total of 63 patients (52 males) with a mean age of 46.2 years were studied. The mean duration of symptoms at presentation was 10.3 months. Myeloneuropathy (54%) was the commonest neurological manifestation, followed by myeloneuropathy with cognitive dysfunction (34%), and peripheral neuropathy (9%). Neuropsychiatric manifestations and dementia were observed in 38% and 19% of patients respectively. All the patients had megaloblastic changes in the bone marrow smear. Eleven (17.5%) patients had both hemoglobin and the mean corpuscular volume (MCV) within the normal range. Follow-up after at least six months of therapy with parenteral B12 showed improvement in 54% patients. CONCLUSIONS: A high index of suspicion of B12def is required in patients presenting with myelopathy, cognitive decline, or neuropathy. A normal hemoglobin or MCV does not exclude B12def; therefore, other tests such as bone marrow smear and serum vitamin B12 assay are essential, as the condition is often reversible with treatment.en_US
dc.description.affiliationNeurology Unit, Department of Neurological Sciences, Christian Medical College, Vellore 632-004, Tamil Nadu, India.en_US
dc.identifier.citationAaron S, Kumar S, Vijayan J, Jacob J, Alexander M, Gnanamuthu C. Clinical and laboratory features and response to treatment in patients presenting with vitamin B12 deficiency-related neurological syndromes. Neurology India. 2005 Mar; 53(1): 55-8; discussion 59en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/120139
dc.language.isoengen_US
dc.source.urihttps://neurologyindia.comen_US
dc.subject.meshAdulten_US
dc.subject.meshCognition Disorders --drug therapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeripheral Nervous System Diseases --drug therapyen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshVitamin B 12 --administration & dosageen_US
dc.subject.meshVitamin B 12 Deficiency --complicationsen_US
dc.titleClinical and laboratory features and response to treatment in patients presenting with vitamin B12 deficiency-related neurological syndromes.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Neurology India